Alpha MD is a multi-disciplinary Healthcare and Life Sciences consultancy with offices in London, Mumbai and Philadelphia. We specialise in early stage market access; research, development and regulatory affairs; and Business Intelligence in healthcare and life sciences. This can include putting together teams for stage one or stage two trials, organising trials for medical devices, and business analytics.
We also have a doctor-patient facing app “Liberate Health” which captures everything that happens during a face to face consultation between doctor and patient, and allows the doctor to send the consultation to the patient by e mail. The patient can review the consultation as many times as they wish. This increases efficacy and patient education. Liberate is especially good for the elderly, infirm, marginalised and those with low levels of health education. Liberate also leaves an EHR.
As a part of our Pre-clinical offering, Alpha MD helps in human biospecimen procurement. We source and deliver leading edge, high quality biospecimens covering the Asian population. We specialise in the procurement of diseased and normal, fresh and frozen blood; FFPE, fresh and frozen tissue; serum, plasma, urine and other biofluids. We collect biomaterials covering all major disease targets in Oncology, Autoimmune and Metabolic disorders, Neurology, Kidney diseases, Pulmonology, Infectious diseases, OB/GYN and others.
We also work with “Clinerion”, a piece of software which is attached to an EHR and is proven to quickly identify patients for clinical trials.
Douglas Barrett – Alpha MD. firstname.lastname@example.org
Watch our Member Showcase video here https://bit.ly/3nJdnGL
Streamline sample storage, identification and handling with AltemisLab™
Founded by an experienced team with considerable industry knowledge. AltemisLab utilises this expertise to deliver the highest quality products and exceptional service.
Helping customers to map workflows and identify the tools that will realise practical, financial and time saving benefits.
The founders of AltemisLab have been working with 2D barcoded tubes since 2000, when this technology was first used by pharmaceutical companies for compound storage.
Using our knowledge and experience we have set out to perfect 2D tube design and we are proud to introduce our AlteTube range of sample storage tubes.
AltemisLab 2D barcoded tubes, barcode readers, de-capping, capping, and handling equipment symbolise a new era of efficiency. With AltemisLab you can rest assured that compliance, quality control and manufacturing excellence are unrivalled.
Watch our Member Showcase Video https://youtu.be/Ge_Fag8PAvg
Development of new drug for the treatment of intracranial haemorrhage.
AMSBIO supplies research products and custom services to the biological and pharmaceutical industries. We sell products for routine laboratory procedures as well as more specific, cutting-edge technology. Areas of specific expertise include physiologically realistic cell culture (including 3D culture), tissues and biorepositories, Zymolyase, glycobiology, lentivirus, ELISA kits and stem cell technology. We also offer custom services in protein expression, histochemistry, peptide/antibody design and 3D culture. With offices in the UK, Germany, Switzerland and the USA, AMSBIO offers fast delivery of material. For more information, please visit www.amsbio.com or contact AMSBIO’s multilingual help team.
Watch our Member Showcase video here https://bit.ly/3HZMe9T
Photobiotics is developing an antibody-drug conjugation platform called OptiLink which enhances an antibody fragment's ability to be chemically loaded with therapeutic drugs or imaging agents. This results in high drug loading, more favourable drug-like properties and appropriate pharmacokinetics. Our lead product is an antibody-directed phototherapy (ADP) drug, which targets tumours and is activated by a laser. Our skills lie in antibody engineering and novel drug design/synthesis. We are working with academic groups, biotech companies and pharmaceutical companies to add value to their technologies and looking for further opportunities.
Longer form - Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, UCL and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). Apollo provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.. . Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes.
Appleyard Lees is a leading intellectual property law firm with over 40 patent and trade mark attorneys and specialist solicitors, providing clients worldwide with a full spectrum of advice and a fully integrated approach to all aspects of IP. With a global reach and local knowledge, we are experts in patents, trade marks, IP strategy, designs, copyright, contentious proceedings and disputes. From offices in Manchester, Leeds, Halifax, Cambridge and Alderley BioHub, we support some of the world's most innovative businesses and leading academic institutions, helping them to maximise the value of their intellectual property throughout its entire life cycle.
Aqdot is a specialist chemical company with a focus and expertise in intelligent encapsulation technology. . . Aqdot’s proprietary technology and know-how enables valuable active products to be protected, delivered and programmed to release where and when required. This unique and disruptive platform technology has the potential to be game-changing in a wide range of industries, including household products, fragrances, personal care, agrochemicals, composites / resin curing and pharmaceuticals. . . Identifying unmet needs in these sectors, we develop products that enable our customers to introduce novel and differentiated products, reduce manufacturing costs, and make a truly positive impact on the environment.
Arecor is the world leader at improving the durability of biologic medicines. Using a rational approach to formulation design, Arecor has generated proprietary technology for stabilising therapeutic proteins, antibodies and vaccines. Arecor has partnered with the world’s largest pharmaceutical companies to enable previously impossible delivery and use options for biologics. As an example of how effective these technologies are – in over 90 per cent of the cases – Arecor’s technology can enable: solid-to-liquid re-formulations; removal of cold-chain; high-concentration delivery, e.g. 200+ mg/ml; and co-formulation of incompatible components.